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Abstract
Heterozygous mutations in the melanocortin-4 receptor (MC4R) gene represent the most frequent cause of monogenic
obesity in humans. MC4R mutation analysis in a cohort of 77 children with morbid obesity identified previously unreported
heterozygous mutations (P272L, N74I) in two patients inherited from their obese mothers. A rare polymorphism (I251L,
allelic frequency: 1/100) reported to protect against obesity was found in another obese patient. When expressed in
neuronal cells, the cell surface abundance of wild-type MC4R and of the N74I and I251L variants and the cAMP generated by
these receptors in response to exposure to the agonist, a-MSH, were not different. Conversely, MC4R P272L was retained in
the endoplasmic reticulum and had reduced cell surface expression and signaling (by <3-fold). The chemical chaperone
PBA, which promotes protein folding of wild-type MC4R, had minimal effects on the distribution and signaling of the P272L
variant. In contrast, incubation with UBE-41, a specific inhibitor of ubiquitin activating enzyme E1, inhibited ubiquitination of
MC4R P272L and increased its cell surface expression and signaling to similar levels as wild-type MC4R. UBE41 had much less
profound effects on MC4R I316S, another obesity-linked MC4R variant trapped in the ER. These data suggest that P272L is
retained in the ER by a propensity to be ubiquitinated in the face of correct folding, which is only minimally shared by MC4R
I316S. Thus, studies that combine clinical screening of obese patients and investigation of the functional defects of the
obesity-linked MC4R variants can identify specific ways to correct these defects and are the first steps towards personalized
medicine.
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Introduction
As the incidence of obesity in children and adolescents has risen
dramatically in occidental countries [1], numerous studies have
focused on understanding its cause. This has led to the
identification of different forms of monogenic obesity, with
mutations in the melanocortin-4 receptor (MC4R) gene, a single
exon gene on 18q22, being the most frequent [2]. MC4R is a G-
protein coupled receptor (GPCR) expressed in the brain where its
activation is involved in the control of food intake and energy
expenditure [3–6]. Fasting induces the expression of orexigenic
neuropeptides including Agouti-related peptide (AgRP) [7], while
fed conditions stimulate the expression of proopeiomelanocortin
(POMC), the precursor to alpha-melanocyte stimulating hormone
(a-MSH) [8]. The balance between the effects of these two
neuropeptides on MC4R activation is critical to control food
intake, energy expenditure and body weight [3–6]. Neurons
producing a-MSH project to neurons in the hypothalamic
paraventricular nucleus, where this neuropeptide binds to
MC4R leading to activation of adenylate cyclase-dependent
production of cAMP. Another population of neurons located in
the hypothalamic arcuate nucleus synthesize the MC4R antago-
nist AgRP [3,7,9]. Activation of MC4R leads to suppression of
food intake and food seeking behavior [3–6], emphasizing the
importance of this system in controlling body weight.
The first cases of obesity due to MC4R mutations were reported
in 1998 [10,11], with the prevalence of mutations in this gene now
estimated at 1/1000 and accounting for up to 6% of severe obesity
cases [2,12]. Since then, more than 150 different MC4R variants
have been described [2,13–15]. Carriers of obesity-linked MC4R
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variants present increased body mass index (BMI), hyperphagia,
and hyperinsulinemia [2]. Characterization of MC4R mutations in
in vitro cell systems has resulted in the identification of different
mechanisms by which obesity-linked MC4R variants can cause
defective function [16]. In approximately 85% of the cases studied
to date the cell surface expression of the receptor is decreased, with
MC4R being retained in an intracellular location [13,17–19]. We
have recently reported that obesity-linked MC4R variants are
misfolded in the endoplasmic reticulum (ER) and targeted for
degradation by ER-associated degradation (ERAD) [20]. In
addition, some of the obesity-linked MC4R variants have defective
binding affinities and/or signaling responses to endogenous or
synthetic agonists [13,21]. Here we present a study where 77
children with early onset morbid obesity were screened for
mutations in MC4R. We found 2 new variants, P272L and N74I,
in MC4R. The cellular localization, signalling properties upon
agonist stimulation and possible pharmacological rescue of these
new mutations are reported.
Patients and Methods
Ethics Statement
This study was approved by the Ethics Committee for Clinical
Investigation at the Hospital Infantil Universitario Nin˜o Jesu´s
(Madrid, Spain) with the protocol number R-0014/10 and written
informed consent was given by parents or guardians on behalf of
the patients.
Patients
To be included in the study the patient had to be prepubertal
and obese (defined as BMI.3 SDS for the Spanish population
according to their chronological age and sex), with no signs of any
syndromic abnormality or other disease. The obesity had to be of
early onset (before 3 yrs of age). A total of 77 white children (50
males and 27 females) were invited to participate.
Mutation analysis
DNA from the proband and first degree relatives was extracted
from peripheral lymphocytes using a Qiagen Midi Kit (Qiagen,
Hilden, Germany). Control DNA samples from 200 healthy white
donors were from the National DNA Bank (Salamanca, Spain).
The MC4R gene was PCR-amplified and Sanger-sequenced
(primers and conditions available upon request). To assess the
putative outcome of the detected non-synonymous single nucle-
otide changes, we used the Condel tool that provides a consensus
deleteriousness score based on the combination of various tools
(http://bg.upf.edu/condel/about; [22]).
Reagents and Antibodies
Lipofectamine 2000 and the mouse monoclonal anti-FLAG
antibodies were purchased from Invitrogen (Carslbad, CA). Rat
monoclonal anti-hemaglutinin (HA) antibody (3F10), peroxidase
(POD)-conjugated anti-HA antibody, POD-conjugated anti-
mouse IgG, protease inhibitor (Complete Mini), and 2,29-azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid (ABTS) tablets were from
Roche Applied Science (Indianapolis, IN); a-MSH, 3-isobutyl-1-
methylxanthine (IBMX) and 4-phenyl butyric acid (PBA) were
from Sigma-Aldrich (St. Louis, MO); POD-conjugated anti-mouse
IgG was from Pierce Biotechnology, Inc (Rockford, IL); Cy3-
conjugated anti-rat and Cy3-conjugated anti-rabbit IgG antibod-
ies were from Jackson ImmunoResearch (West Grove, PA). Rabbit
polyclonal anti-calnexin, mouse monoclonal anti-KDEL and the
cAMP ELISA Kit were from Enzo Life Sciences (San Diego, CA).
The enhanced chemiluminescence detection kits were from
PerkinElmer Life Sciences, Inc (Boston, MA). The ubiquitin
activating enzyme inhibitor (UBE1–41) was from Biogenova
(Maryland, USA) [23]. Neuroblastoma Neuro2A (N2A) cells were
a kind gift from Peter Cserjesi, (Tulane University, New Orleans,
LA).
Constructs
TheWTHA-MC4R-GFP plasmid was described earlier [24]. The
primers used to generate HA-MC4R-GFP (N74I, P272L and I251L)
mutants were 59GGCAATAGCCAAGAACAAGATCCTGCATT-
CACCCATG39, 59TTCTACATCTCTTGTCTTCAGAATCCA-
TATTGTGTGTGC39 and 59ACCTTGACCATCCTGCTTG-
GCGTCTTTGTTGTC39. All mutations were confirmed by
sequencing. Plasmid DNA for transfections into mammalian cells
was isolated using the DNA purification system from Promega. Flag-
ubiquitin was a kind gift from Dr. JoAnn Trejo, University of North
Carolina at Chapel Hill.
Cell culture, transfection and drug treatment
N2A cells (American Type Culture Collection, Manassas, VA,
USA) were cultured in DMEM with 10% fetal bovine serum and
penicillin/streptomycin. Cells were transiently transfected using
lipofectamine 2000 by following the manufacturer’s instructions.
Experiments were carried out 48 h after transfection unless
indicated otherwise. For drug treatment, vehicle alone (DMSO)
or 2 mM PBA was added 16 h after transfection and maintained
until the cells were harvested. For the inhibition of ubiquitination
20 mM UBE1–41 was added 16 h before the cells were harvested.
Gel electrophoresis and immunoblotting
Separation of proteins by SDS-PAGE and immunoblotting with
the indicated antibodies were performed as described [20]. Unless
noted otherwise, cell lysates were prepared by scraping cells from
60 mm diameter plates in 0.4 ml of sample buffer containing
protease inhibitors. Samples were sonicated 3 times for 2 s periods
and loaded onto SDS-PAGE.
Immunoprecipitation
Transfected cells grown in 60 mm dishes were scraped in
immunoprecipitation (IP) buffer (100 mM Tris-HCl, pH 7.4,
50 mM NaCl, 1% Triton, and protease inhibitors) and incubated
for 30 min at 4uC. Cell lysates were rotated for 1 h at 4uC with the
indicated antibody. After addition of protein A/G beads, the
samples were further incubated for 1 h at 4uC. After three washes
with IP buffer the beads were resuspended in sample buffer, boiled
for 5 min, and centrifuged. Supernatants and cell extracts were
loaded onto a SDS-PAGE gel.
Fluorescence microscopy
Epifluorescent images were captured with a CARV I spinning
confocal imaging system (BioVision Technologies, Exton, PA)
attached to an X-71 fluorescence microscope (Olympus, Tokyo,
Japan). Images were collected using a CoolSNAP HQ camera
(Photometrics, Tucson, AZ). Confocal images were captured using
an Olympus FluoViewTM FV1000 confocal microscope and
analyzed by using ImageJ software version 1.33 by Wayne
Rasband (NIH, Bethesda, Maryland).
Quantification of MC4R expressed at the cell surface
Cells were washed three times with DMEM and incubated in
DMEM for 1 h at 37uC, DMEM was aspirated, cells were
transferred on ice and incubated in the same medium with rat
monoclonal anti-HA antibodies for 1 h at 4uC. Cells were then
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fixed with 4% formaldehyde, washed with PBS, and incubated
with PBS containing 100 mg/ml ovalbumin and Cy3-conjugated
anti-rat antibodies without addition of detergents. Cells expressing
HA-MC4R-GFP were chosen at random and the Region of
Interest (ROI) was drawn on the merged image around the
compartment labeled by the HA antibodies using ImageJ software.
The amount of HA-MC4R-GFP at the cell surface was estimated
by measuring the fluorescence intensity of the receptor in the Cy3
channel.
Quantification of HA-MC4R-GFP at the cell surface by
enzyme-linked immunoassay
HA-MC4R-GFP at the cell surface by enzyme-linked assay was
determined as described previously [24]. Briefly, N2A cells
transiently transfected as indicated were washed three times with
DMEM and incubated in DMEM for 1 h at 37uC. Cells were
further incubated for 1 h at 4uC in the same medium in the
presence of POD-conjugated anti-HA antibodies (25 mU/ml).
Cells were washed 2 times with ice-cold DMEM and fixed with
formaldehyde at 4uC for 10 min. Cells were washed 3 times with
PBS and POD activity was determined by using the ABTS
substrate to measure the amount of receptor at the cell surface.
Assay to determine cAMP
Cells were washed with DMEM and incubated with the same
medium containing 0.5 mM IBMX for 10 min and then
stimulated with 100 nM a-MSH for 15 min at 37uC. The
medium was aspirated and intracellular cAMP was measured by
using the immunoassay kit by Enzo life technologies following the
manufacturer’s instructions.
Statistical Analysis
Data are expressed as mean 6 S.D. GraphPad Prism version
5.0 (GraphPad software, San Diego, CA) was used to perform
unpaired t-test or one-way analysis of variance (ANOVA).
Statistical significance was chosen as p,0.05.
Results
Two novel MC4R mutations, P272L and N74I, identified in
obese patients
Two novel heterozygous mutations were identified in unrelated
patients from this cohort of 77 cases with early onset severe obesity
(2.6%), as well as a rare polymorphism in a third case.
Case #1: A white male had a novel c.815C.T (p.P272L)
mutation in MC4R (Fig. 1A) inherited from his mother who also
had early-onset obesity. The patient was born at 33 weeks of
gestation with a birth weight of +3.2 SDS and birth length in the
85th percentile. At presentation he was 610/12 yrs old with a BMI
of +5.6 SDS.
Case #2: A male of Arabic ancestry carried a novel
c.221_222AT.TC (p.N74I) MC4R mutation (Fig. 1B) inherited
from his obese mother. His birth weight was +2.09 SDS at 40
weeks of gestation (length unknown). At presentation he was 27/
12 yrs old with a BMI of +4.8 SDS.
Case #3: A previously described MC4R polymorphism
(rs52820871, p.I251L; Fig. 1C) was identified in a female that
was obese from the first months of live. She was 10 yrs old at
clinical evaluation with a BMI of +3.7 (SDS).
The P272L and N74I mutations have not been described in the
SNP database (www.ncbi.nih.org/projects/SNP) nor in 6,503
controls (13,006 chromosomes) included in the exome-variant-
server database [25]. In addition, none of the 200 healthy
individuals from Spain tested carried either mutation. To assess
the putative outcome of the detected non-synonymous single
nucleotide changes, we used the Condel method [22] that provides
a consensus deleteriousness score based on the combination of
various tools. The scores of different methods (SIFT, Polyphen2
and MutationAssessor) are weighted using the complementary
cumulative distributions produced by the five methods on a
dataset of approximately 20000 missense SNPs, both deleterious
and neutral. The probability that a predicted deleterious mutation
is not a false positive of the method and the probability that a
predicted neutral mutation is not a false negative are employed as
weights (http://bg.upf.edu/condel/about; [22]). Any Condel
score above 0.5 is considered as likely deleterious, with the
maximun score being 1. By this analysis, integrating protein
structure and interaction predictions with conservation informa-
tion, both mutations are predicted to be highly deleterious, with
N74I having a Condel score of 1 and P272L a score of 0.99. These
mutations are located in the 1st intracytoplasmatic loop and the 3rd
extracellular loop, respectively. In contrast, the I251L variant,
located in the 6th transmembrane domain, is found in ,0.9% of
chromosomes and predicted to be functionally neutral with a
Condel score of 0.
P272L-MC4R variant is retained in the ER
Mutated HA-MC4R-GFP P272L expression at the cell surface
was decreased compared to the wt-receptor (26.05610.81%,
Fig. 2A), suggesting that this variant is retained in an intracellular
compartment. HA-MC4R-GFP N74I and I251L were expressed
at the cell surface at levels similar to wt. Cell surface expression of
N74I- and I251L-HA-MC4R-GFP, measured by immunofluores-
cence, was similar to wt, while that of HA-MC4R-GFP P272L was
decreased (Fig. 2B and 2C), which is consistent with the POD-
based immunoassay data (Fig. 2A). All mutants had reduced total
MC4R expression compared to wt, as estimated by GFP
fluorescence, with the greatest effect observed in the P272L
mutant (Fig. 2D). The ratio of Cy3 fluorescence (receptor at the
plasma membrane)/GFP fluorescence (total receptor) indicates the
fraction of total receptor at the plasma membrane. This ratio was
Figure 1. Chomatograms of the three identified MC4R mutations. Chromatograms of MC4R P272L (A), MC4R N74L (B) and MC4R I251L (C).
doi:10.1371/journal.pone.0050894.g001
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decreased by approximately 3-fold for the obesity-associated HA-
MC4R-GFP P272L mutant as compared to wt, indicating
intracellular retention similar to other obesity-associated MC4R
mutants that are misfolded in the ER (Fig. 2E) [20]. Conversely,
the fraction of N74I and I251L receptor at the cell surface was
increased. Thus, the variants have different cellular distribution,
with HA-MC4R-GFP P272L being retained in the ER with
increased colocalization with the ER chaperone calnexin (Fig. 2F)
and with HA-MC4R-GFP N74I and I251L having a reduced total
pool of receptors, but an increased fraction of receptor at the
plasma membrane.
The amount of intracellular cAMP per mg of cell protein
produced after a-MSH stimulation was unchanged in N2A cells
expressing HA-MC4R-GFP N74I or I251L and reduced by
approximately 70% in the P272L mutation compared to wt
(Fig. 2G). The amount of cAMP produced per receptor at the cell
surface was unaffected (Fig. 2H), suggesting that HA-MC4R-GFP
P272L, N74I and I251L do not have defective signalling.
Inherent propensity to be ubiquitinated, rather than
misfolded, retains MC4R P272L in the ER
We have previously shown that cell exposure to a chemical
chaperone, PBA, increases plasma membrane expression of wt-
MC4R and of some obesity-associated MC4R variants that are
retained in the ER [20]. UBE1-41, a specific inhibitor of ubiquitin-
activating enzyme 1 [23], also improved cell surface expression of
wt-MC4R and of the obesity-associated MC4R I316S variant
[20]. The effects of PBA and UBE1-41 were additive, suggesting
that the two drugs affect MC4R exit from the ER by targeting
steps that are, at least in part, independent of each other. Here, in
a similar experimental approach (Fig. 3A), we found that UBE-41
promoted not only increased expression of wt-HA-MC4R-GFP at
the cell surface (Fig. 3B), but also increased agonist-dependent
generation of cAMP (Fig. 3C). Therefore, it appears that a drug
that specifically inhibits ubiquitination can, by itself, promote exit
of functional MC4R from the ER. These experiments suggest that
although a population of wt-MC4R can fold correctly it
nevertheless has the propensity to be ubiquitinated, and that this
feature contributes to its retention in the ER. The effects induced
by PBA on cell surface expression and signaling of wt-HA-MC4R-
GFP were similar in magnitude to those induced by UBE1-41 (by
,2-fold, Fig. 3B). Conversely, exposure to UBE-41 increased cell
surface expression and signaling by HA-MC4R-GFP P272L to a
much higher extent than that observed after exposure to PBA (by
,1.4-fold for PBA and by ,3-fold for UBE-41, Fig. 3B). Thus, in
the case of MC4R P272L, as compared to wt-MC4R, most of HA-
MC4R-GFP P272L retained in the ER is because of the receptor’s
tendency to be ubiquitinated, rather than to misfold.
The mechanism by which MC4R P272L and MC4R I316S
are retained in the ER is different
The results shown in Figure 3 demonstrate that functional
MC4R P272L can be rescued to the cell surface more efficiently
by UBE-41 than by PBA exposure. This is different than what was
observed for another obesity-linked variant retained in the ER,
MC4R I316S, which was rescued to the cell surface similarly by
UBE-41 and by PBA exposure [20]. This posed the question as to
whether obesity-linked receptor variants differ in the main
mechanism by which they are retained in the ER, with MC4R
I316S having more propensity to misfold and then to be
ubiquitinated and with MC4R P272L being ubiquitinated in the
face of correct folding. We reasoned that a different response to
UBE-41 exposure might help discriminate differences in the
Figure 2. Cellular localization of the distinct MC4R mutations.
A) N2A cells were transfected with wt-HA-MC4R-GFP and mutated HA-
MC4R-GFP (N74L, I251L and P272L) or incubated at 37uC for 48 h.
Receptor at the cell surface was measured by enzyme-linked
immunoassay. Data are expressed as percentage of the wt receptor,
(n = 3). B) N2A cells were transiently transfected as in A. Cells were
transferred at 4uC, incubated with primary rat monoclonal anti-HA
antibodies, fixed, and incubated with secondary Cy3-conjugated anti-
rat antibodies. C–E) Quantification of the confocal images of the
experiment shown in B. The ratio of HA-MC4R-GFP at the cell surface/
total receptor in the cell (E) was estimated by dividing the fluorescence
intensity of the receptor at the cell surface (Cy3, C) by the fluorescence
intensity of the receptor in the entire cell (GFP, D). wt-HA-MC4R-GFP
(n = 64) and mutated HA-MC4R-GFP (N74L n = 111, I251L n = 74 and
P272L n = 72). Statistical significance, *** = p,0.0001. F) N2A cells were
transiently transfected with wt-HA-MC4R-GFP and mutated HA-MC4R-
GFP P272L and incubated at 37uC for 48 h. Cells were fixed, incubated
with primary rabbit polyclonal anti-calnexin antibodies (Enzo Life
Science, Farmingdale, NY) and with secondary Cy3-conjugated anti-
rabbit antibodies. G–H) N2A cells were transiently transfected with wt-
HA-MC4R-GFP and mutated HA-MC4R-GFP (N74L, I251L or P272L) and
incubated at 37uC for 48 h. Cells were stimulated with 100 nm a-MSH
for 15 min at 37uC. Intracellular cAMP was measured by using the
immunoassay kit by Assay Designs (San Diego, CA), following the
manufacturer’s instructions. The amount of cAMP generated was
expressed as pmols cAMP/mg prot (G), and pmols cAMP/receptor at
the cell surface (H), (n = 3). ).
doi:10.1371/journal.pone.0050894.g002
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mechanism by which MC4R P272L and MC4R I316S are
retained in the ER. To monitor the extent by which HA-MC4R-
GFP P272L and I316S are ubiquitinated, the receptors were co-
expressed with FLAG-ubiquitin. The amount of HA-MC4R-GFP
in the cell with and without UBE-41 treatment was measured by
Western blot analysis of the immunoprecipitated receptor and the
extent of its ubiquitination by the associated Flag immunoreac-
tivity. In the absence of UBE-41, the percentage of ubiquitinated
HA-MC4R-GFP P272L was less than HA-MC4R-GFP I316S
(,37% and 60% respectively, Figs. 4A and 4B). After exposure to
UBE1-4, the total amount of HA-MC4R-GFP P272L and I316S
was increased similarly, by approximately 5-fold (Fig. 4A). This
indicates that inhibition of ubiquitination leads to decreased
disposal of MC4R both in the case of the P272L and of the I316S
variants. However, the fraction of ubiquitinated HA-MC4R-GFP
was decreased by ,70% in the case of the P272L variant and by
,25% in the case of MC4R I316S variant (Figs. 4A and 4B). This
experiment shows that I316S can still be ubiquitinated under
conditions where most of P272L is not. Importantly, treatment
with UBE-41 improved cell surface expression of MC4R P272L
by more than 70%, measured both by immunoassay (Fig. 4C) and
by immunofluorescence (Figs. 4D and 4E). Conversely, MC4R
I316S expression at the cell surface was only increased by ,25%
by the treatment with the inhibitor (Figs. 4C–E). These data
indicate that under conditions where the ubiquitination capacity of
the cell is decreased, the propensity of MC4R P272L to be
ubiquitinated is also reduced and traffic of the receptor outside the
ER to the cell surface is restored. This is different from MC4R
I316S, which, under the same conditions, remains mostly
ubiquitinated and localized to the ER.
Discussion
We describe two novel heterozygous mutations in the MC4R
gene associated with early onset morbid obesity in childhood.
These mutations, P272L and N74I, are predicted to be highly
deleterious and cosegregate with obesity in the respective kindred.
In contrast, the I251L variant is found in almost 1% of
chromosomes and predicted to be functionally neutral.
When studied in an in vitro system, the P272L mutation was
retained in the ER failing to reach the plasma membrane, which
resulted in reduced signaling after agonist stimulation. Thus,
retention in the ER and poor expression of the MC4R P272L
mutant at the cell surface could explain the obese phenotype
observed in patients carrying this mutation. In contrast, we cannot
explain the pathogenic mechanism of the N74I and I251L MC4R
variants, if any, as expression at the plasma membrane and
intracellular cAMP generation appeared to be normal after
heterologous transfection of the mutant constructs. However, the
N74I described here resulted in a reduction in the total number of
MC4R/cell suggesting a deleterious effect. The pathogenic
mechanism of this mutation might depend on the interaction of
the mutant with the wild-type protein in heterozygous individuals
and thus be missed by our approach. Whether the affinity of the
receptor for one or both of its endogenous ligands, AgRP and a-
MSH, is affected by these mutations remains to be determined.
Furthermore, as expression of this receptor on presynaptic
terminals is also important for metabolic control [26], it is possible
that trafficking of the N74I mutated receptor to other cellular
locations is affected. Likewise, MC4R has been recently shown to
be expressed in astrocytes [27]. Given the recent interest in
Figure 3. Functional studies and rescue of the mutation P272L. A) N2A cells were transiently transfected with wt-HA-MC4R-GFP and mutated
HA-MC4R-GFP-P272L and treated with vehicle or 2 mM PBA, 20 mM UBE-41 or both at the time points indicated in the diagram. B) Receptor at the
cell surface from cells in A was measured by a spectrophotometric assay. Data are expressed as percentage of the wt without treatment, (n = 3). C)
Intracellular cAMP from cells in A was measured by using the immunoassay kit by Assay Designs (San Diego, CA), following the manufacturer’s
instructions. The amount of cAMP generated by was expressed as pmols cAMP/mg protein, (n = 3). Statistical significance,
* = p,0.05,** = p,0.001,*** = p,0.0001, ns = p.0.05.
doi:10.1371/journal.pone.0050894.g003
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astrocyte involvement in metabolic control [28], modifications in
its expression and functions in this cell type could also possibly be
involved in producing an obese phenotype.
We have recently reported that some obesity-linked MC4R
variants are retained in the ER because they are misfolded [20]. In
the same study, we found that the chemical chaperone PBA can
increase folding and plasma membrane expression of wt-MC4R
and of some obesity-linked MC4R variants including I316S, with
increased signaling after stimulation with the agonist. In contrast,
here we show that the MC4R P272L variant can be rescued to the
cell surface more efficiently by decreasing its ubiquitination than
by treating with PBA to increase ER folding capacity. These
results suggest that most of MC4R P272L is retained in the ER due
to an intrinsic tendency to be ubiquitinated, rather than misfolded
and then ubiquitinated. In this respect, MC4R P272L rescued at
the cell surface by cell incubation with UBE-41 is functional,
demonstrated by an increase of signaling after agonist stimulation
that parallels its increase at the cell surface. The results presented
here suggest that strategies aimed to decrease ubiquitination of
some obesity-linked variants could be a main target for novel
therapeutic approaches.
UBE-41 inhibits the ubiquitin activating enzyme (E1) [23],
which catalyzes the first step on the ubiquitination reaction and is
not substrate-specific. In contrast, the ubiquitin protein ligases
(E3), which catalyze the last step of the ubiquitination process, are
substrate-specific and therefore represent a more suitable thera-
peutic target [29]. Whether silencing of E3 is able to increase
surface expression and function of obesity-linked MC4R variants
and whether modulation of the activity of E3 in vivo could protect
against the obesity associated with mutations in MC4R are topics
to be addressed in future studies.
The frequency of MC4R gene mutations found in the
population of obese children reported here (1.4–2.6%) is lower
than in other studies, 5.8% [2,12–19]. This could be related to the
strict selection of patients, including only those with extreme
obesity very early in life. Thus, mutations causing a less severe or
delayed form of obesity were not included. The polymorphism
I251L associated with obesity in the patient described here is
reported to protect against obesity [21,30–32]. This variant
increased the fraction of MC4R localized at the plasma
membrane, but decreased overall abundance of the receptor.
While it is possible that the obesity presented by this subject is not
related to this polymorphism, further studies are necessary to
understand the intracellular trafficking and function of the I251L
variant as the protective effects of this polymorphism are surely
influenced by other genetic factors.
In conclusion, the results reported here emphasize the
importance of functional studies in order to determine the
mechanisms involved in monogenic obesity, with these functional
studies possibly paving the way for the development of personal-
ized medical treatment of specific forms of obesity.
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